BridgeMD
New treatment option for Multiple Sclerosis, Relapsing-Remitting
Official title Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
ClinicalTrials.gov ID: NCT03401879
What this study is testing
- What it's testing
- Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- for healthy people:
- Men and women aged over 18 years
- Non-smokers
- Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropy \< 6 Dpt. for patients with MS:
See the full eligibility criteria
- for healthy people:
- Men and women aged over 18 years
- Non-smokers
- Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropy \< 6 Dpt. for patients with MS:
- Men and women aged over 18 years
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to clinical evaluation and McDonald criteria (revision 2010)
- History of AON in one eye at least one year ago
- Non-smokers
- Normal ophthalmic findings, ametropy \< 6 Dpt.
- Adequate visual acuity to allow participation in the ocular blood flow measurements
- A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except MS therapy itself which will be recorded separately) for at...
- Diagnosis of "possible MS" according to the McDonald criteria (revision 2010)
- Presence or history of a severe medical condition as judged by the clinical investigator
- Untreated Arterial hypertension
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Family history of MS, optic neuritis, neuromyelitis optica (NMO, Devic disease) or NMO spectrum disorders
- History of inflammatory or infectious disease of central nervous system
- Best corrected visual acuity \< 0.5 Snellen
- Ametropy ≥ 6Dpt
- Pregnancy or planned pregnancy
- Alcoholism or substance abuse Any of the following will exclude a patient from the study:
- Presence or history of a severe medical condition other than MS as judged by the clinical investigator
- History of neuromyelitis optica (NMO, Devic disease) or NMO spectrum disorders
- History of inflammatory or infectious disease of central nervous system other than MS
- Untreated Arterial hypertension
- History or family history of epilepsy
- Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
- Best corrected visual acuity \< 0.5 Snellen
- Ametropy ≥ 6 Dpt
- Pregnancy, planned pregnancy
- Significant neurological disease other than MS, if considered relevant by the investigator
- Alcoholism or substance abuse
The study team makes the final eligibility decision.
Where it's taking place
- Vienna, Austria, Austria
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vienna, Austria, Austria. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.